Analysts Set Certara, Inc. (NASDAQ:CERT) Price Target at $8.28

Shares of Certara, Inc. (NASDAQ:CERT) have been assigned a consensus recommendation of “Hold” from the eleven brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $8.2778.

A number of equities research analysts recently issued reports on CERT shares. Robert W. Baird dropped their target price on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Tuesday, May 12th. BMO Capital Markets reduced their price target on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Tuesday, May 12th. Weiss Ratings upgraded shares of Certara from a “sell (e+)” rating to a “sell (d)” rating in a research report on Wednesday, August 5th. Barclays upped their price objective on shares of Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Finally, Craig Hallum cut their target price on shares of Certara from $10.00 to $8.00 and set a “hold” rating for the company in a research note on Tuesday, May 12th.

Hedge Funds Weigh In On Certara

A number of institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC acquired a new stake in shares of Certara in the first quarter valued at $259,000. Goldman Sachs Group Inc. lifted its position in Certara by 65.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after buying an additional 90,724 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Certara by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after buying an additional 35,954 shares in the last quarter. Jane Street Group LLC grew its holdings in Certara by 17.1% during the 1st quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after acquiring an additional 40,463 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Certara by 29.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock worth $1,089,000 after acquiring an additional 21,099 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Price Performance

Shares of CERT stock opened at $7.94 on Monday. The stock’s fifty day simple moving average is $7.63 and its 200 day simple moving average is $6.52. Certara has a one year low of $4.45 and a one year high of $13.88. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -17.64 and a beta of 1.40. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 2.55.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $93.27 million for the quarter, compared to analyst estimates of $98.09 million. Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The business’s revenue was down 10.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.07 earnings per share. On average, analysts expect that Certara will post 0.22 earnings per share for the current fiscal year.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.